Antiviral medications are among the options that doctors are considering as a way to treat the disease. But there is still an unknown as to which ones might work best.
Category: healthcare
Study Says Obese People Should Quarantine Longer
For 28 days, suggests researchers.
A Dose of Disney May Help Women Undergoing Chemotherapy
Watching Disney movies can improve quality of life for some women diagnosed with gynecologic cancers.
Why Haven’t We Seen The Data On Remdesivir?
Enthusiasm for remdesivir as a treatment for COVID-19 is growing despite the fact that full results from the NIH trial have yet to be released.
Humana Expands ‘Bold Goal’ Quality Initiative To 16 Cities
A project by Humana to improve health through better management of patient populations will be expanded to 16 U.S. communities.
Scientists See Progress In Treatment Of COVID-19
A group of Hong Kong Physicians report in Lancet that a cocktail of drugs approved for the treatment of other viral diseases significantly improved the clinical and laboratory outcomes of hospitalized COVID-19 patients.
Pricing Of COVID-19 Treatments And Coronavirus Vaccines
Healthcare providers and patients are hoping that effective COVID-19 treatments and coronavirus vaccines will be widely available soon. However, regulatory approval is just the first step in determining patient access. Any approved treatment must be av…
Americans Want To Stop The Pandemic And Save The Economy, But Our Brains Like The Easy Way Out
The pandemic is not going away any time soon, and that makes the next phase of COVID-19 harder than the first. But our brains have a secret: they’ll do anything to get out of hard work.
Five Things Big Pharma—And Its Investors—Could Learn From Synthetic Biology
Drug discovery is becoming slower and more expensive over time, despite better, cheaper tools in technology and biology. Can COVID shake pharma from its inertia? Can synthetic biology save drug makers?
Five Things Big Pharma—And Its Investors—Could Learn From Synthetic Biology
Drug discovery is becoming slower and more expensive over time, despite better, cheaper tools in technology and biology. Can COVID shake pharma from its inertia? Can synthetic biology save drug makers?
